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Abstract
Background: Neuroblastoma is a severe pediatric tumor, histologically characterised by a variety of cellular
phenotypes. One of the pharmacological approaches to neuroblastoma is the treatment with retinoic acid. The
mechanism of action of retinoic acid is still unclear, and the development of resistance to this differentiating agent is a
great therapy problem.
Doublecortin, a microtubule-associated protein involved in neuronal migration, has recently been proposed as a
molecular marker for the detection of minimal residual disease in human neuroblastoma. Nevertheless, no information
is available on the expression of doublecortin in the different cell-types composing human neuroblastoma, its correlation
with neuroblastoma cell motility and invasiveness, and the possible modulations exerted by retinoic acid treatment.
Methods: We analysed by immunofluorescence and by Western blot analysis the presence of doublecortin,
lissencephaly-1 (another protein involved in neuronal migration) and of two intermediate filaments proteins, vimentin
and neurofilament-68, in SK-N-SH human neuroblastoma cell line both in control conditions and under retinoic acid
treatment. Migration and cell invasiveness studies were performed by wound scratch test and a modified
microchemotaxis assay, respectively.
Results: Doublecortin is expressed in two cell subtypes considered to be the more aggressive and that show high
migration capability and invasiveness.
Vimentin expression is excluded by these cells, while lissencephaly-1 and neurofilaments-68 are immunodetected in all
the cell subtypes of the SK-N-SH cell line. Treatment with retinoic acid reduces cell migration and invasiveness, down
regulates doublecortin and lissencephaly-1 expression and up regulates neurofilament-68 expression. However, some
cells that escape from retinoic acid action maintain migration capability and invasiveness and express doublecortin.
Conclusion: a) Doublecortin is expressed in human neuroblastoma cells that show high motility and invasiveness;
b) Retinoic acid treatment reduces migration and invasiveness of the more aggressive cell components of SK-N-SH cells;
c) The cells that after retinoic acid exposure show migration and invasive capability may be identified on the basis of 
doublecortin expression.
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Neuroblastoma (NB), the most common extracranial
solid paediatric tumor, is responsible for approximately
15% of cancer deaths occurring in childhood. In older
patients the prognosis is still poor although the clinical
course may be protracted [1]. Consistent with their origin
from neural crest-derived multipotent precursors, NBs are
often composed of multiple cellular phenotypes. This het-
erogeneity is retained in some cell lines derived from these
tumors.
In SK-N-SH cell line, derived from a bone marrow metas-
tasis, at least three cell types are present: the sympathoad-
renal neuroblasts (N), the substrate-adherent non-
neuronal (S), and the intermediate (I) cells. [2,3]. The N-
type are small rounded cells with short neuritic processes,
whereas the S-type are large, flat and strongly attached to
the substrate. The I-type have a morphology intermediate
between that of N and S, are moderately adherent to the
substrate and show small cell body with or without neu-
ritic elongations. In addition, the I-type cells have the abil-
ity of forming aggregates in culture [3]. The three cell types
differ also in the capability to induce the tumor; it has
been reported that N-type cells are malignant while the S-
type are not, but surprisingly, the I-type cells have the
greatest malignancy [2]. Moreover, it has been hypothe-
sized that the I-type, may be recognized as tumor stem
cells, capable of both self-renewal and bidirectional differ-
entiation, being the progenitor of both N- and S-type [4].
The current treatment of NB may involve surgery, chemo-
therapy, radiation therapy, megatherapy with stem cell
rescue and biological approaches [5]. Arrest of cell growth
and morphological differentiation can be observed after
retinoic acid (RA) treatment at particular stages of progres-
sion of the disease, but the precise mechanism of action of
RA remains uncharted; moreover, resistance to RA repre-
sents a significant drawback to its clinical utility.
In recent years, a number of genetic and biological fea-
tures have been investigated in the effort to identify tumor
markers that would improve cure rates.
Doublecortin (DCX), a microtubule associated protein,
has been proposed as a new molecular marker to detect
minimal residual disease in human NB, since it has been
detected in all the tumors analyzed and it appears to be
more efficient than tyrosine hydroxylase [6].
Moreover, DCX, semaphorin3B and SPARC (Osteonec-
tin), three genes that play key roles in cellular migration
processes, have been indicated as prognosticators of poor
prognosis in human glioblastoma [7].
Recently, it has also been reported that DCX is present in
tumors of the human central and peripheral nervous sys-
tem [8] and that is preferentially expressed in invasive
human brain tumors [9].
DCX is the product of the X-linked gene doublecortin
(Xq22.3-Xq23) and is required for neuroblastic migration
during development of the cerebral cortex [10]. Mutations
in this gene result in a deficient neuronal migration that
gives rise to the X-linked lissencephaly in males or to the
subcortical laminar heterotopia (doublecortex) in female
patients [11,12]. DCX is expressed in migrating neurons
throughout the central and peripheral nervous system
during embryonic and postnatal development, regulates
the microtubule cytoskeleton and it is involved in
dynamic morphological changes [13-15] and in nuclear
translocation occurring during neural cell migration. In
this process it acts synergistically with lissencephaly-1
(LIS1), another microtubule associated protein codified
by the gene Lis1, located on chromosome 17p.13.3
[16,17]. LIS1 localizes predominantly to the centrosome
and acts with DCX for the correct nucleus-centrosome
coupling required for normal neuronal migration [17].
To date, the presence of DCX in human NB has been eval-
uated only by real-time RT-PCR in tumor samples [6], and
by Western blot (WB) analysis in SH-SY5Y cell line [18].
However it is not known whether DCX is expressed in all
the different cell-types (S, N and I) composing the tumor
or it is a characteristic of some of them, and whether its
interacting protein LIS1 is also expressed in the human
NB.
In the present study we have analysed by immunofluores-
cence (IF) the presence of DCX and LIS1 in the different
cell subtypes that constitute the SK-N-SH neuroblastoma
cell line. We have also correlated the intracellular localiza-
tion of these two proteins with tubulin and with two inter-
mediate filaments: vimentin (VIM) and neurofilament-68
(NF-68) that have been utilized as possible cell-subtype
specific markers. Furthermore, we have investigated by IF
and WB analysis whether a treatment with the differenti-
ating agent RA might induce modifications on DCX, LIS1,
VIM and NF-68 expression. In addition, motility and inva-
siveness of SK-N-SH cells have been studied by wound
scratch test [19] and by a modified microchemotaxis assay
[20], so as to evaluate the capability of RA to influence
these parameters.
Methods
Cell cultures
Human SK-N-SH cells were grown as a monolayer in
Eagle's Minimum Essential Medium (MEM) supple-
mented with 10% of heat-inactivated Foetal Bovine
Serum (FBS from Gibco, Invitrogen), 1% non essentialPage 2 of 12
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pyruvate, penicillin (20 units/ml) and streptomycin (20
mg/ml), and were maintained at 37°C in a saturated
humid atmosphere with 5% CO2. As they approached
confluence, the cells were split following treatment with
Trypsin-EDTA. The seeding density varied according to the
type of experiment.
DCX sequence analysis
Genomic DNA from the SK-N-SH cell line was prepared
using standard procedures [21]. Sequence analysis of the
DCX gene coding regions was performed essentially as
described previously [11]. Briefly, the 7 DCX coding exons
(exons 1C-7; NCBI Ac. Nos. AJ005592-AJ005597) and
their flanking intron sequences were amplified by PCR
and directly sequenced using an automated sequencing
apparatus (3100 Genetic Analyzer, Applied Biosystems,
Foster City, CA).
Treatment with Retinoic Acid
All-trans RA (Sigma) was added to a final concentration of
10 μM, according to known pharmacological dosages
used in phase I trials of RA administered orally to NB
patients [22]. Moreover, it has been well established that
addition of 10 μM RA to proliferating NB cells induces
their differentiation [23]. To study RA effects on SK-N-SH
cell line, cells were plated at a density of 5 × 105cells/10
cm diameter Petri dish for WB at a density of 5 × 103cells/
13 mm diameter well for IF or alternatively at a density of
2 × 104cells/13 mm diameter well for the scratch wound
assay, and grown in MEM medium supplemented as
described above. RA was first dissolved in absolute etha-
nol and then supplemented with DMSO to achieve a con-
centration of 10-3 M in ethanol-DMSO (87.5%–12.5%).
This stock solution was kept at -20°C. For each experi-
ment RA was diluted at the desired concentration directly
into the growth medium. Cells cultured in medium con-
taining 0.1% of ethanol-DMSO (87.5%–12.5%) were
used as control. The 10 μM RA treatment started on the
second day after plating, concomitantly with the medium
replacement. Cells were fed every 48 hr with control, or
RA- containing fresh medium and the treatment was
stopped 2, 4, 6 or 12 days after the first addition of RA. In
order to investigate whether the effect of RA on DCX pro-
tein expression was reversible, we treated SK-N-SH cells
with RA for 6 days; afterwards the cells were grown in con-
trol medium for 6 additional days.
Antibodies
For both IF and WB the primary antibodies used were:
anti-DCX (C-18 sc-8066; 1:500) and anti-LIS1 (H-300 sc-
15319; 1:200) from Santa Cruz Biotechnologies, anti-
vimentin (1:10,000) and anti-neurofilaments-68
(1:1,000) from Chemicon International and anti-α-tubu-
lin (1:500) from Sigma.
Immunofluorescence analysis
Cells were grown on 13 mm diameter coverslips, fixed in
4% paraformaldehyde (PFA), permeabilized in 0.2% Tri-
ton X-100 and then, the unspecific sites were blocked in
10% normal donkey serum (Sigma) in PBS. Subsequently,
cells were incubated with the primary antibodies for 1 hr
at room temperature and then rinsed with PBS. For triple-
label IF, Cy3-conjugated anti-goat (for anti-DCX anti-
body), Cy2-conjugated anti-rabbit (for anti-LIS1, or alter-
natively for anti-neurofilaments-68 antibody) or AMCA-
conjugated anti-mouse (for anti-α-tubulin or alternatively
anti-vimentin antibody) secondary antibodies (Jackson
ImmunoResearch) were used (1 hr at room temperature).
The manufacturer guarantees the use of these secondary
antibodies for multiple labelling procedures, since they
are purified against cross-reactivity to other species.
Nuclei were stained with DAPI (Sigma-Aldrich). Finally,
the cells were washed in PBS before mounting using
Mowiol 40–88 (Sigma-Aldrich).
Western blot analysis
Cells were lysed with modified RIPA buffer (TRIS-HCl 50
mM pH7.4, NaCl 150 mM, Tryton X-100 0.1%, Na-deox-
ycholate, EDTA 0.1 M, SDS 1%) containing protease
(ABESF, leupeptin and pepstatin) and phosphatase inhib-
itors (NaF 1 mM, Na3VO4 1 mM). For alkaline phos-
phatase treatment, cells were lysed with the
aforementioned RIPA cell lysis buffer without phos-
phatase inhibitors (1 mM NaF and 1 mM Na3VO4) and
then the cell lysates were incubated at 37°C for 30 min-
utes with calf intestinal alkaline phosphatase (CIP, 1 unit/
μg of protein; Amersham Biosciences).
The total protein content for each sample was measured
using the Bradford's method. 50–70 μg of proteins were
separated on SDS-12% PAGE under reducing conditions
and transferred onto nitrocellulose membranes. After
blocking for 45 minutes at room temperature in 5% non-
fat-milk in PBS, membranes were probed overnight at
4°C, with the primary antibodies diluted in 5% milk-PBS;
they were subsequently washed with PBS and incubated
with secondary antibodies coupled to horseradish peroxi-
dase. The secondary antibodies used were HRP-conju-
gated- anti-goat (for anti-DCX antibody), anti-rabbit (for
anti-LIS1 or for anti-neurofilamente-68 antibody), and
anti-mouse (for anti-α-tubulin or anti-vimentin anti-
body) from Santa Cruz Biotechnologies. Detection and
visualization of protein-bound antibodies was achieved
using an enhanced chemiluminescence WB detection kit
(ECL Plus, Amersham Biosciences). To quantify the inten-
sity of the bands, membranes were scanned and analysed
with the NIH Image software. All data are normalized
against tubulin and expressed as percentage of the control.Page 3 of 12
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In order to investigate SK-N-SH cell migration capability
after RA treatment, a modified wound scratch assay was
used [19,24]. Briefly, the treated and untreated cells were
grown to confluent monolayer on 13 mm diameter glass
coverslips. On the 6th day of treatment, approaching
100% cell confluence, the monolayers were wounded by
scratching the surface as uniformly as possible with a
pipette tip. This initial wounding and the movement of
the cells in the scratched area was photographically mon-
itored using the Axiovert Zeiss 200 microscope with a 10×
(NA 0.25) objective linked to a Coolsnap Es CCD camera
(Roper Scientific – Crisel Instr. Rome) for 24 hr. This time
interval has been chosen because it is shorter than SK-N-
SH doubling time. Four different fields from each sample
were considered for quantitative estimation of the dis-
tance between the borderlines and in each image four dif-
ferent equidistant points were measured in order to better
estimate the real width of the wounded area. The migra-
tion rate is expressed as percentage of the control, and it
was calculated as the proportion of the mean distance
between both borderlines caused by scratching, to the dis-
tance which remained cell-free after re-growing [24]. Two
independent series of experiments were performed in
quadruplicates. To evaluate the correlation between DCX
protein expression and cell migration capability, at the
end of the photographic monitoring, the cells were fixed
in 4% PFA and immunostained with anti-DCX antibody.
Cell invasion assay
Cell invasion was determined by a modified microchem-
otaxis assay [20] using cell culture 24-well inserts with the
bottom sealed by a 8 μm pore polycarbonate-filter coated
with Matrigel (Chemicon International, Inc.). Briefly, 2.5
× 105 cells in 250 μl of serum-free MEM were seeded into
the inserts. The lower chambers were filled with MEM
additioned of 10%FBS. Chambers were incubated at 37°C
in a 5% CO2 atmosphere for 48 hr. The cells that did not
migrate through the filter were scraped from the insides of
the inserts. The cells migrated to the underside of the
coated filter were fixed in 4% paraformaldehyde for 5
min, washed two times with PBS and then processed for
DCX IF analysis. Nuclei were stained with DAPI (Sigma).
Alternatively, the migrated cells were incubated with cell
detachment buffer and dissociated from the filter. The
cells were then lysed and stained by CyQuant GR dye. Flu-
orescence was counted using VICTOR3™ multilabel read-
ers (PerkinElmer®). Data are expressed as means ±
standard error, N = 4.
Image acquisition
Images were acquired using the UIC-Metavue 6.2.2 (UIC-
Crisel Instr. Rome) imaging system on an Axiovert Zeiss
200 microscope. An oil immersion 63× (NA 1.4) or a 40×
(NA 0.8) objective was used for IF images. To estimate the
number of DCX-positive DCX+) or VIM-positive (VIM+)
cells, at least 4 different images related to 3 control and 3
treated samples were considered. In each image acquired,
the DCX+ and the VIM+ cells were counted. Data are graph-
ically expressed as the ratio between the number of DCX+
or VIM+ cells to the number of the cells counted in total.
For the wound scratch test analysis, images were acquired
using a 10× (NA 0.25) objective. The distance between the
borderlines of the scratched area was measured using the
Region Measurement Function included in UIC-Metavue
6.2.2 (UIC-Crisel Instr. Rome) software.
Statistical analysis
Results of quantitative analysis are presented as means ±
standard error (S.E.); the number of samples varied
between a minimum of 4 and a maximum of 8 depending
on the experimental protocol. Control and treated sam-
ples have been compared by the one-sided unpaired Stu-
dent's t-test or by ANOVA and using the GraphPad Prism
software (version 4.0). The results are considered statisti-
cally significant versus the untreated cells, with a proba-
bility level of p < 0.05 (*), or statistically highly significant
with a probability level of p < 0.01 (**).
Results
DCX is present in the N- and some I-type cells, but not in 
the S-type, of SK-N-SH cell line
As already reported [2,3] the three different cell types
composing SK-N-SH cell line were distinguishable by
phase contrast (PC) microscopy analysis (Fig. 1A and 1F).
IF analysis for DCX shows a clear signal (DCX+) in all the
cells with the N morphological phenotype and in some I-
type, while it is absent (DCX-) in the S-type cells (Fig. 1).
In the cells that express DCX this protein is present in the
cell body and all along the neuritic elongations, and, as
expected due to its microtubule associated protein nature,
it colocalizes with tubulin (Fig. 1).
Since tumoral cells in culture may undergo genetic insta-
bility the possible presence of DCX deleterious mutations
was considered and ruled out by direct sequence analysis
(see Materials and Methods) of the SK-N-SH DCX gene
coding regions (data not shown).
Since DCX can form etherodimers with LIS1, we also eval-
uated LIS1 expression and we found its immunoreactivity
in all the SK-N-SH cell subtypes, with a stronger signal in
DCX+ cells (Fig. 1).
To further characterize the cell subtypes not only on the
basis of DCX expression, we considered other markers,
such as VIM and NF68.Page 4 of 12
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(VIM+) that is totally absent (VIM-) in the N-type cells
(Fig. 1). A double staining for DCX and VIM clearly shows
an exclusive expression in the different cell types; in fact,
these proteins never colocalize in any cell type observed.
Among the cells with an intermediate morphology we
identified at least three subpopulations: the first one
shows immunoreactivity for DCX but not for VIM; the sec-
ond one displays an opposite expression pattern of the
two proteins; and the third one expresses neither DCX nor
VIM (Fig. 1). NF-68 immunoreactivity is present in all the
cells, even if the N-type shows a higher signal.
Effects of exposure of SK-N-SH cells to retinoic acid
As expected, 10 μM RA treatment induces a clear morpho-
logical differentiation of SK-N-SH N-type cells shown by
the extension of their neuritic processes, Some S-type cells
appear more elongate, but do not acquire a completely
different phenotype (Fig 2).
In terms of DCX, after 2 (Fig. 2 panel M) or 4 days (data
not shown) of RA exposure it is possible to observe a
decreased stain in N-type cells while, in the same cell, the
signal for VIM increases. After a longer (6 days) RA treat-
ment, DCX immunoreactivity disappears from almost all
of the N-type cells and it is replaced by VIM signal (Fig 2).
The S-type cells remain DCX-, whereas VIM is always
present even if the fluorescence signal is unchanged or
slightly reduced (Fig. 2). A quantitative evaluation of the
number DCX+ and VIM+ cells, regardless of their morphol-
ogy, confirms that RA exposure leads to a decrease in the
number of DCX+ cells and to an increase in that of VIM+
(Fig 2 panel K and L).
Regarding NF-68, RA treated cells show a more intense
signal, in particular the N-type cells that underwent differ-
entiation (Fig. 2).
After RA treatment, we also observe the same three sub-
populations of I-type cells recognized in untreated cul-
tures; moreover at this time interval, LIS1
immunostaining is apparently reduced, nevertheless it is
still present in all cell types (data not shown).
WB analysis clearly shows double immunoreactive bands
for DCX in SK-N-SH (Fig. 3). This doublet resolves to a
single band after calf intestine alkaline phosphatase (CIP)
treatment, indicating that the slower-migrating species
correspond to phosphorylated DCX (Fig. 3), as already
described [14,25]. However, since we observed prelimi-
narily that RA treatment reduced the amount of both DCX
forms, and in order to better quantify the decrease of its
expression, in the following experiments we run the sam-
ples to get a single immunoreactive band for DCX, and
DCX and vimentin are expressed by different SK-N-SH neu-roblastoma cell subtypesFigure 1
DCX and vimentin are expressed by different SK-N-SH neurob-
lastoma cell subtypes. The sets of figures A-E and F-J are representa-
tive of a series of images taken from SK-N-SH cells cultured in control 
conditions. PC analysis (panels A and F) clearly shows the heterogeneity 
of the cell population. The triple IF for DCX (B), LIS1 (C) and TUB (D) 
shows an immunoreactive signal for DCX only in the N-type and in some 
I-type cells. The anti-LIS1 antibody stains all the cell types. When co-
expressed by the same cell, TUB and DCX colocalize both in the cell body 
and along the neuritic processes (see inset 1 of panel E). The triple IF for 
DCX (G), NF-68 (H) and VIM (I) shows that none of the DCX+ cells is 
immunoreactive for VIM. Vimentin is present merely in the S-type and in 
some I-type DCX- cells. Some other I-type cells do express neither DCX 
nor VIM (arrow in the inset 2 of panel J). The NF-68 protein is expressed 
by all the cell subtypes.Page 5 of 12
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Six days RA treatment reduces the number of DCX+ cells and increases that of VIM+ cellsFigure 2
Six days RA treatment reduces the number of DCX+ cells and increases that of VIM+ cells. Figures here reported are representative of a series 
of images taken from SK-N-SH cells cultured in control conditions (A-E) or after six days RA treatment (F-J). PC analysis (panels A and F) shows morpho-
logical changes induced by RA. After 6 days RA treatment the DCX+ cells are few (G) in comparison to the control (B), and they have the morphology of 
undifferentiated I-type cells. On the contrary is increased the number of VIM+ cells and the differentiated N-type VIM+ cells do not show immunoreactivity 
for DCX (I). Bar graphs show the decrease in the number of DCX+ cells (K) and the increase in the number of VIM+ cells (L) after RA treatment. Bars 
represent mean ± standard error, N = 8, double star = p < 0.01. Neither in control nor in 6 days RA treated samples there are DCX-/VIM- cells immuno-
positive for both DCX and VIM, but as previously observed in control conditions (see fig.1), some DCX-/VIM- cells are present after RA treatment (see the 
cell marked with *, panel J). As in the controls (C), NF-68 localizes in all RA treated SK-N-SH cells (H). It is important to note that after the first 2 days of 
treatment it is possible to observe N-type cells (white arrows) that start to express VIM while DCX is disappearing (M).
BMC Cancer 2008, 8:30 http://www.biomedcentral.com/1471-2407/8/30utilized an anti-DCX antibody which reacts with both the
phosphorylated and the unphosphorylated DCX forms
[25].
Protein analysis reveals that the exposure of SK-N-SH cells
to RA for 6 days significantly decreases both DCX (-
87.4%) and LIS1 (-38.4%) levels, whereas NF-68 protein
content (+86.3%) increases and VIM remains unchanged
(Fig. 4).
A time-course WB analysis shows that 2- or 4 days treat-
ment with RA significantly reduces DCX levels (Fig. 5)
without modifying those of LIS1, VIM and NF-68 (data
not shown). The DCX low level, observed after 6 days
treatment, is not further diminished by extending RA
exposure up to 12 days. Moreover, the down regulation
exerted by 6 days RA exposure on DCX persists after an
additional 6 days period following treatment withdrawal
(Fig 5).
Only DCX expressing cells show spontaneous motility 
after RA treatment
To evaluate the motility of SK-N-SH cells we have then
analyzed their response to wound healing assay, either in
control conditions or after RA treatment.
As shown in Fig. 6, untreated SK-N-SH cells are able to
invade the scratched area that is fully re-colonised 24 hr
later. IF analysis shows that all the cells moving in the
scratched area are DCX+ (Fig. 6).
Six days RA treatment strongly reduces the migration rate
of the SK-N-SH cells. In fact, 24 hr after the scratch very
few cells are in the scratched area and the distance
between the borders of the wound is not significantly dif-
ferent from that measured immediately after the scratch
(Fig. 6 panel A). The few cells that move into the scratched
area are DCX+, most of them have short or no neurites,
and small and refractile cell bodies (Fig. 6 panel B and C).
Quantitative analysis clearly indicates a significant (about
-40%) decrease of the cell migration rate following RA
treatment (Fig. 7).
Neuroblastoma cells with invasive activity are DCX+
NB cell invasiveness has been evaluated by means of a
modified microchemotaxis assay. Cells cultured in nor-
mal conditions or treated with RA for 6 days were seeded
into culture well containing polycarbonate membranes
inserts coated with a film of Matrigel. After 48 hr, invasive
cells migrated through the matrix-membrane unit and
attached to the bottom of the membrane were dislodged
and their number was estimated using a nuclear fluores-
cent dye. The results obtained show that RA treatment sig-
nificantly reduces the amount of NB cell able to invade
the Matrigel (chart of Fig. 8).
Some of the insert membranes have been processed for IF.
Invading cells attached to the bottom of the membrane
were fixed and immunostained for DCX. We found that,
in both control and RA treated samples, all the cells
migrated through the matrix/membrane unit are DCX+,
even with different intensity (Fig. 8, right panels).
Discussion
In the present study we demonstrate a differential expres-
sion of DCX in the cell subtypes composing human NB
cell line SK-N-SH. DCX appears to be expressed exclu-
sively in the cells that show high motility and invasive-
ness; these parameters are reduced by RA treatment that
also down regulates DCX expression. It is noteworthy to
say that after RA treatment all the cells that maintain
motility and invasiveness express DCX.
DCX is a microtubule-associated protein (MAP) mainly
involved in cell migration [10,12]. Modifications of DCX
expression in neuron-like cell and its possible correlation
with motility/invasion has been studied in mouse or in rat
experimental models. For instance, it has been demon-
strated that overexpression of DCX increases mouse neu-
ronal migration rates in vitro [17]. On the contrary,
targeted mutation or the shutdown of DCX disrupts the
migration of neuronal cells [26,27].
Even though by the present data a direct involvement of
DCX in these mechanisms cannot be assessed, to our
knowledge this is the first evidence that in human NB cell
line SK-N-SH DCX is specifically expressed in neuroblastic
(N-type) cells, but it is absent in substrate adherent (S-
type) cell type. Moreover, DCX is expressed in some, but
not all, cells possessing an intermediate phenotype (I-
type). Since it is sometime quite difficult to clearly distin-
guish the I-type from the N-type cells by their morphol-
ogy, we found easier to identify the cells composing SK-N-
DCX and phospho-DCX (P-DCX) expression in SK-N-SH cell lineFigur  3
DCX and phospho-DCX (P-DCX) expression in SK-N-SH cell 
line. Lysates (50 μg/lane) of SK-N-SH control and 6 days RA treated cells 
were processed with or without calf intestine alkaline phosphatase (CIP) 
and analyzed by WB. DCX is a phosphoprotein and appears as a doublet 
that resolves to a single band after CIP treatment (+CIP) in both C and RA 
samples, indicating that the slower-migrating species is phosphorylated 
DCX (P-DCX).Page 7 of 12
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Six days RA treatment lowers DCX and LIS1 protein levels while NF-68 content increasesFigure 4
Six days RA treatment lowers DCX and LIS1 protein levels while NF-68 content increases. WB representative images and results of the den-
sitometric analysis (A-D). After 6 days RA treatment the protein level of DCX (A) decreases by 87.4% and that of LIS1 (B) by 38.4%; NF-68 protein 
amount increases by 86.3% (C). Data related to VIM (D) show high variability and do not indicate any change in protein level after RA treatment. C, con-
trols; RA, samples treated with 10 μM RA for 6 days. Bars represent mean ± standard error, N = 8 and data are expressed as a percentage of the control 
(100%); single star = p < 0.05; double star = p < 0.01.
BMC Cancer 2008, 8:30 http://www.biomedcentral.com/1471-2407/8/30SK cell line as DCX-expressing (DCX+) or DCX-not-
expressing (DCX-) cells.
In addition, we show that also in NB cells this protein
colocalizes with tubulin, as already reported for mouse
and human migrating neurons [13,28,29].
The data here reported indicate for the first time that LIS1,
another MAP that may dimerize with DCX in migrating
neurons [16], is expressed in all the cell types composing
SK-N-SH cell line. It is well known that DCX-LIS1 interac-
tion plays a role in nucleus-centrosome coupling during
neuronal migration [17]. Therefore, it is possible to pos-
tulate that LIS1-DCX interaction would play a role also in
DCX+ NB cell nucleokinesis and, possibly, in NB cell
motility.
Moreover, here we report the presence of DCX in the two
cell types (N- and I-type) that are indicated as the most
malignant component of NB [2]. Actually, the results
obtained by scratch-wound-healing assay and cell inva-
siveness test, clearly indicate that in control conditions all
the cells that move into the scratched area and invade the
Matrigel-coated membrane are DCX+. It is noteworthy to
say that all the DCX+ cells, the only that show motility and
invasiveness, express LIS1; the solely expression of LIS1 in
DCX- cells excludes a role of it in spontaneous motility.
Of interest is the observation that VIM, an intermediate
filament protein characteristic of non-neuronal and non-
tumorigenic NB cell types [2,3], is present only in DCX-
and not in DCX+ cells. This exclusive expression of DCX or
VIM represents an additional parameter to identify differ-
ent NB cell subtypes. Therefore, beside the well recogniz-
able N-type and S-type cells, our results evidence at least
three cell subtypes with a I-type morphology: DCX+, DCX-
/VIM+ and, in a small amount, cells lacking both DCX and
RA treatment reduces SK-N-SK neuroblastoma cell motilityFigu  6
RA treatment reduces SK-N-SK neuroblastoma cell motility. (A) 
Representative PC images of untreated (Control) or 6 days RA treated 
cells which motility has been analyzed by scratch test. Images show the 
starting (0 hr after scratch) and the end (24 hr after scratch) point of the 
analysis. In control the distance between the borderlines becomes signifi-
cantly shorter 24 hr after wounding, while it is still elevated in RA treated 
samples. (B) IF DCX analysis performed both in control and in RA treated 
cells 24 hr after wounding. In control samples the majority of invading cells 
are DCX+ (red). Even if the migration rate of the treated cells is reduced, 
few of them move in and invade the scratched area; all the cells still 
migrating after 6 days RA treatment are DCX+ (inset 1 and 2 of panel B 
are magnified in panel C). Nuclei are counterstained with DAPI (blue).
DCX down regulation is time dependent and irreversibleFigure 5
DCX down regulation is time dependent and irreversible. WB 
representative image (A): lysates (50 μg/lane) of SK-N-SH control and RA 
treated cells at different time intervals (2, 4, 6, 6 plus 6 of withdrawal and 
12 days) were analyzed by immunoblotting using an anti-DCX specific anti-
body; membranes were reprobed with anti-tubulin as a loading control. 
Quantification of DCX protein amount by scanning densitometry (B): 
data are means ± standard error, N = 8, and are expressed as a percent-
age of the control (100%). After 2 or 4 days of RA treatment DCX levels 
are significantly decreased, but to a lesser extent than after a 6 days expo-
sure to RA. Lengthening SK-N-SH exposure to RA up to 12 days does not 
modify the magnitude of the DCX reduction observed after 6 days of 
treatment. Moreover, in cells treated with RA for 6 days and then grown 
for 6 additional days in medium without RA (6 days+6), DCX protein 
amount remains at low levels; single star = p < 0.05; double star = p < 
0.01; C, control, RA, samples treated with RA 10 μM.Page 9 of 12
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explanation for the meaning of these three I-cell subtypes,
however further studies are now in progress in the
authors' lab.
RA treatment is known to cause differentiation of NB N-
type cells into a more mature phenotype and to induce
changes in the expression of specific markers [30,31].
Our data, while confirming previous evidences, show a
progressive decrease of DCX expression during the RA-
induced differentiation of N-type cells. As a consequence,
the number of DCX+ cells is greatly reduced by the treat-
ment.
On the contrary, S-type cells are slightly affected by the
treatment, and we did not observe any of these cells
becoming DCX+. This observation confirms once more
that RA acts specifically upon N-type cells [30,31]. In N-
type cells, we observe that DCX level starts to decrease
after 2 days of RA exposure and reaches the lowest value
after 6 days of treatment. It should be noted that DCX
level remains very low also after RA treatment withdrawal.
Altogether, the results here reported indicate that DCX
down-regulation starts very early after the onset of RA
treatment, it is progressive, time-dependent, and irrevers-
ible.
Also LIS1 expression is reduced after RA treatment, but
there are no cells completely lacking LIS1. Therefore, it
can be argued that this protein is not directly correlated
with cell differentiation.
In the present paper, we also report that SK-N-SH cell
motility is greatly reduced by RA. The only cells able to
move from the scratched borderlines into the wounded
area are the few DCX+ ones still present after the treat-
ment. In accordance to scratch test results, we also demon-
strate that RA exposure is able to reduce NB cell
invasiveness; the only cells that invade the Matrigel-
coated membrane are DCX+. This last observation under-
lines the importance of DCX as a marker for invasive NB
cells.
The results here reported indicate that NB cell motility
and invasiveness are characteristics of DCX+ cells, and
that, also after RA treatment, both of these capabilities are
retained only by the cells expressing this protein.
Joshi and coworkers reported that 24 hr of RA exposure
stimulates SH-SY5Y cell migration and invasiveness,
while long term treatment (5 days) is less effective in stim-
ulating migration but significantly reduces invasiveness
[32]. Voight and co-workers [24] demonstrated that 3
days RA treatment does not modify cell migration of SK-
N-FI, SH-SY5Y, SK-N-MC and SK-N-LO NB cell lines. In
RA treatment reduces SK-N-SH neuroblastoma cell invasive-nessFigu  8
RA treatment reduces SK-N-SH neuroblastoma cell invasive-
ness. Invasiveness of NB cells is significantly reduced after 6 days RA 
treatment. The amount of invasive cells has been evaluated by means of a 
fluorescence assay (see Materials and Methods). Data are expressed as rel-
ative fluorescence units (RFU). Columns are means ± standard error; N = 
4; double star = p < 0.01. Representative images of the cells on the bot-
tom side of the insert filter show that all NB cells invading the matrix are 
DCX+ (red) in both control and RA treated samples. Nuclei are counter-
stained with DAPI (blue).
Quantification of RA effect on neuroblastoma cell motilityFigure 7
Quantification of RA effect on neuroblastoma cell motility. Graph 
shows that NB cell migration rate of 6 days RA treated cells (RA) is signif-
icantly reduced in comparison with untreated cells (C). Data are obtained 
from a set of scratch test analysis and are expressed as means ± standard 
error; N = 4;double star = p < 0.01.Page 10 of 12
(page number not for citation purposes)
BMC Cancer 2008, 8:30 http://www.biomedcentral.com/1471-2407/8/30addition, SH-SY5Y cells showed a slight reduction in
migratory capability whereas invasiveness was signifi-
cantly reduced after 3 days of RA treatment [24]. In this
regard, it is important to underline that our results on SK-
N-SH motility have been obtained by scratching the cell
monolayer after 6 days RA treatment, when DCX expres-
sion reaches the lowest values.
We have also observed that after RA treatment the cell
motility is retained by the cells expressing both DCX and
LIS1 but not by those cells expressing LIS1 alone.
Interestingly, we found that DCX and VIM signals may
colocalize in the same N-type cell during short exposure
to RA; however, after prolonged exposure, differentiated
N-type cells loose DCX immunoreactivity and acquire a
VIM positive phenotype. Although this effect is clearly evi-
dent by IF analysis, WB quantitation performed on the
whole SK-N-SH cell population does not show VIM
increase. This might probably be due to the concomitant
slight decrease of VIM expression in S-type cells as
observed by IF. Actually, using a NB cell line deprived of
S-type cells, other authors have documented a significant
increase of VIM expression after RA treatment [4]. Given
the fact that motility and invasiveness are characteristics
of DCX+/VIM- cells, it is possible to postulate that VIM
could be a marker not only of S-type cells [2,3], but also
of those N-type cells that assume a DCX-/VIM+ phenotype
in response to RA treatment. This hypothesis is supported
by the proposed role of VIM for axonal elongation in dif-
ferentiating NB cells [33].
Finally, we have also observed that after RA treatment all
the three I-cell subtypes (DCX-/VIM-; DCX+/VIM-; DCX-/
VIM+) are still present. The presence of DCX+ cells might
indicate a resistance of these cells to RA treatment or the
existence of a subpopulation of cells transiently express-
ing this protein during their differentiation process. Actu-
ally, it has been demonstrated that during adult
hippocampal neurogenesis DCX is not expressed by stem
cells, but only by neural progenitor cells and disappears
when progenitor cells differentiate to mature neurons
[34]. We may therefore suppose that RA could induce the
differentiation of DCX-/VIM- I-type cells toward a DCX-/
VIM+ phenotype through an intermediate phase character-
ized by DCX expression. Further studies will be addressed
to specifically test this hypothesis.
Besides the observation that DCX is a marker for the min-
imal residual disease in human neuroblastoma [6], our
results provides the new evidence that this protein is not
present in all cell subtypes composing SK-N-SH cell line
but it is express only in the more aggressive neuroblast-
oma cell subpopulation and in the retinoic acid-resistant
cells that possess high motility and invasiveness.
Conclusion
We report the first demonstration that DCX is differen-
tially expressed only in some (N and I) cell types compos-
ing SK-N-SH human NB cell-line.
All the DCX+ cells show high migratory capability and
invasiveness; moreover, we show that RA treatment
induces a significant reduction of these parameters and
down-regulates DCX expression.
RA is unable to completely block DCX expression in all
the cells, and the few DCX+ cells that are still present after
the treatment show high motility and invasiveness.
We found that the some DCX+ RA-resistant cells have the
morphological features of I-type cells, and since I-type
cells are indicated as the more undifferentiated and
aggressive cellular component of human NB, the presence
of these cells after the treatment might support the emerg-
ing concept about the existence of cancer stem cells liable
to tumor relapse [35]. This last hypothesis is presently
under investigation.
Irrespective of a direct role of DCX in NB cell motility, the
present data suggest that the detection of DCX+ cells in
untreated and treated tumors in neuroblastoma affected
patients may be prognostic of tumor aggressiveness, as
well as of a severe tumor relapse after treatment.
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